An important role of the SDF-1/CXCR4 axis in chronic skin inflammation

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Zgraggen, Silvana ^a   Huggenberger, Reto ^a   Kerl, Katrin ^b   Detmar, Michael ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AM 3100; CHEMOKINE RECEPTOR CXCR4; IMIQUIMOD; NEUTRALIZING ANTIBODY; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; CXCL12 PROTEIN, MOUSE; CXCR4 PROTEIN, MOUSE; STROMAL CELL DERIVED FACTOR 1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSORIASIS; UPREGULATION; ANIMAL; C57BL MOUSE; CHRONIC DISEASE; DERMATITIS; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY;

AMINOQUINOLINES; ANIMALS; CHEMOKINE CXCL12; CHRONIC DISEASE; DERMATITIS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CXCR4; UP-REGULATION;

EID: 84898863120     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093665     Document Type: Article

References (43)

1. Perera GK, Di Meglio P, Nestle FO (2012) Psoriasis. Annu Rev Pathol 7: 385-422.
2. Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445: 866-873.
3. Fuentes-Duculan J, Suárez-Fariñas M, Zaba LC, Nograles KE, Pierson KC, et al. (2010) A Subpopulation of CD163-Positive Macrophages Is Classically Activated in Psoriasis. J Invest Dermatol: Nature Publishing Group. pp. 2412-2422.
4. Huggenberger R, Detmar M (2011) The cutaneous vascular system in chronic skin inflammation. J invest Dermatol 15: 24-32.
5. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, et al. (1994) Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180: 1141-1146. (Pubitemid 24256627)
6. Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, et al. (2001) VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. am J Gastroenterol 96: 822-828. (Pubitemid 32240738)
7. Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, et al. (2005) Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 115: 247-257. (Pubitemid 40385467)
8. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE (1999) Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Brit J Dermatol 141: 1054-1060. (Pubitemid 30046195)
9. Kunstfeld R, Hirakawa S, Hong Y-K, Schacht V, Lange-Asschenfeldt B, et al. (2004) Induction of cutaneous delayed-type hypersensitivity reactions in VEGFA transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 104: 1048-1057. (Pubitemid 39038025)
10. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, et al. (2003) Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102: 161-168. (Pubitemid 36759650)
11. Halin C, Fahrngruber H, Meingassner JG, Bold G, Littlewood-Evans A, et al. (2008) Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol 173: 265-277. (Pubitemid 351947973)
12. Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF (2009) Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. PNAS 106: 21264-21269.
13. Zgraggen S, Ochsenbein AM, Detmar M (2013) An important role of blood and lymphatic vessels in inflammation and allergy. J Allergy 2013: 672381.
14. Kiefer F, Siekmann AF (2011) The role of chemokines and their receptors in angiogenesis. JCell Mol Life Sci 68: 2811-2830.
15. Mirshahi F, Pourtau J, Li H, Muraine M, Trochon V, et al. (2000) SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res 99: 587-594. (Pubitemid 30642740)
16. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, et al. (1999) Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 154: 1125-1135. (Pubitemid 29169747)
17. Forster R, Kremmer E, Schubel A, Breitfeld D, Kleinschmidt A, et al. (1998) Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol 160: 1522-1531. (Pubitemid 28093457)
18. Volin MV, Joseph L, Shockley MS, Davies PF (1998) Chemokine receptor CXCR4 expression in endothelium. Biochem Bioph Res Co 242: 46-53. (Pubitemid 28412374)
19. Pablos JL, Amara A, Bouloc A, Santiago B, Caruz A, et al. (1999) Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin. Am J Pathol 155: 1577-1586.
20. Petit I, Jin D, Rafii S (2007) The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28: 299-307. (Pubitemid 46963141)
21. Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, Krueger JG (2011) Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol 131: 391-400.
22. Zhou X, Krueger JG, Kao MC, Lee E, Du F, et al. (2003) Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol genomics 13: 69-78. (Pubitemid 37129170)
23. Albanesi C, Scarponi C, Pallotta S, Daniele R, Bosisio D, et al. (2009) Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med 206: 249-258.
24. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, et al. (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182: 5836-5845.
25. Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, et al. (2012) IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol 188: 462-469.
26. Hatse S, Princen K, Bridger G, De Clercq E, Schols D (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS letters 527: 255-262. (Pubitemid 35253875)
27. Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, et al. (1998) Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111: 1-6. (Pubitemid 28309201)
28. Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ (2002) AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 160: 1353-1360. (Pubitemid 34411639)
29. Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K, et al. (2010) Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med 207: 2255-2269.
30. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108. (Pubitemid 351818697)
31. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi C, et al. (1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol: American Society for Investigative Pathology. pp. 293.
32. Hirakawa S, Hong Y, Harvey N (2003) Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol.
33. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, et al. (2008) Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 181: 4733-4741.
34. De Klerck B, Geboes L, Hatse S, Kelchtermans H, Meyvis Y, et al. (2005) Proinflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Res Ther 7: R1208-1220.
35. Mikami S, Nakase H, Yamamoto S, Takeda Y, Yoshino T, et al. (2008) Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. J pharmacol Exp Ther 327: 383-392.
36. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, et al. (2001) AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 167: 4686-4692. (Pubitemid 32954350)
37. Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, et al. (2000) Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 165: 6590-6598.
38. Wang H, Beaty N, Chen S, Qi CF, Masiuk M, et al. (2011) The CXCR7 chemokine receptor promotes B-cell retention in the splenic marginal zone and serves as a sink for CXCL12. Blood: 465-468.
39. Halin C, Tobler NE, Vigl B, Brown LF, Detmar M (2007) VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood 110: 3158-3167. (Pubitemid 350106307)
40. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH (2013) Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 133: 2340-2346.
41. Kerfoot SM, Andonegui G, Bonder CS, Liu L (2008) Exogenous stromal cell-derived factor-1 induces modest leukocyte recruitment in vivo. Am J Physiol 294: H2524-2534.
42. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA (1996) A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184: 1101-1109.
43. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, et al. (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acq Immun Def Synd. pp. 1253.